---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-22-189446"
form_type: "8-K"
ticker: "SYRE"
cik: "0001636282"
company_name: "Spyre Therapeutics, Inc."
filed_at: "2022-07-07T23:59:59+00:00"
generated_at: "2026-06-24T19:40:17.408065+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.25
calibrated_materiality_score: 0.25
confidence: "high"
source: SEC EDGAR
---

# Aeglea BioTherapeutics director Sandesh Mahatme resigns, effective July 8, 2022

## Summary
- Sandesh Mahatme resigned as Class I director effective July 8, 2022.
- Resignation not due to any disagreement with company operations, policies, or practices.
- No replacement named at this time.

## SEC filing metadata
- accession: 0001193125-22-189446
- form_type: 8-K
- ticker: SYRE
- cik: 0001636282
- company_name: Spyre Therapeutics, Inc.
- filed_at: 2022-07-07T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.25
- calibrated_materiality_score: 0.25
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1636282/000119312522189446/0001193125-22-189446-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1636282/000119312522189446/d274196d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-22-189446
- JSON: https://secwatch.observer/filing/0001193125-22-189446.json
- Plain text: https://secwatch.observer/filing/0001193125-22-189446.txt

## Key facts
- Executive change
  Sandesh Mahatme resigned as Class I Director at Spyre Therapeutics, Inc..
  - Action: resigned
  - Role: Class I Director
  source text: On July 6, 2022, Sandesh Mahatme advised the Board of Directors (the “Board”) of Aeglea BioTherapeutics, Inc. (the “Company”) that he would resign as a Class I director of the Board, effective on July 8, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1636282/000119312522189446/0001193125-22-189446-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.